

## Special Issue

# Adoptive Cell Therapy against Cancers

### Message from the Guest Editors

Adoptive cell therapy (ACT), especially, chimeric antigen receptor (CAR) T cell therapy, is rapidly growing and have revolutionized the field of immunotherapy for cancer, showing promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure. Barriers to effective ACT include time-consuming and lab-intensive manufacturing, complex logistics, severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration, and so on. To overcome these hurdles, several strategies, from screening the best starting material, developing novel CAR or TCR structures and improving the manufacturing process up to combining ACT with other anti-tumor agents, could be considered to optimize the clinical efficacy of ACT. This Special Issue aims to cover recent advances in adoptive cell therapy including manufacturing, method validation for product specification, logistics study, novel CAR design, combination therapy and clinical trials and therefore seeks for review or original manuscripts addressing one of the aforementioned (or related) topics. We look forward to receiving your contributions.

---

### Guest Editors

Dr. Lei Wang

Dr. Sanmei Wang

Dr. Wenjie Gong

---

### Deadline for manuscript submissions

closed (15 March 2023)



## Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/132903](https://mdpi.com/si/132903)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).